J.B. Chemicals & Pharmaceuticals Limited successfully completed its postal ballot process on March 24, 2026, with shareholders overwhelmingly approving all five proposed director appointments. The pharmaceutical company announced the results following a comprehensive e-voting process that demonstrated strong shareholder support for the new leadership structure.

Postal Ballot Process and Participation

The postal ballot was conducted pursuant to a notice dated January 21, 2026, in accordance with Section 110 of the Companies Act, 2013. The e-voting period remained open from February 22, 2026, at 9:00 a.m. to March 23, 2026, at 5:00 p.m., facilitated through the National Securities Depository Limited (NSDL) portal.

Director Appointment Results

All five ordinary resolutions received substantial shareholder approval, with participation representing 80.99% of the company's total paid-up equity capital of 160,527,546 shares.

Key Appointments Approved

Aman Mehta - Dual Role Appointment The shareholders approved two separate resolutions for Mr. Aman Mehta (DIN: 08174906):

Non-Executive Non-Independent Directors Three additional directors were appointed to strengthen the board:

Director Profiles and Expertise

Aman Mehta - Managing Director Mr. Aman Mehta brings extensive pharmaceutical industry experience as the current Managing Director of Torrent Pharmaceuticals Limited. With a Bachelor's degree in Economics from Boston University and MBA from Columbia University, he has over a decade of experience within the Torrent Group. His appointment as Managing Director is effective for a period of 3 years from January 21, 2026.

Amal Kelshikar - Non-Executive Director Mr. Amal Kelshikar contributes 32 years of experience in strategic planning, marketing, and business development. He holds a BE (Chemical) from University Department of Chemical Technology, Mumbai, and MBA from Indian Institute of Management, Ahmedabad. He has been overseeing India business of Torrent Pharmaceuticals Limited since 2022.

Hasmukh Patel - Non-Executive Director Mr. Hasmukh Patel brings over 33 years of pharmaceutical industry experience, currently serving as Chief Operating Officer at Torrent Pharmaceuticals Limited. He holds a master's degree in pharmacy and has been with Torrent since May 1992, rising from Trainee Scientist to his current leadership role.

Sudhir Menon - Non-Executive Director Mr. Sudhir Menon is a Chartered Accountant and Cost Accountant with over 29 years of experience in finance and corporate management. He currently serves as Executive Director (Finance) & Chief Financial Officer of Torrent Pharmaceuticals Limited, joining the company in May 2006.

Voting Pattern Analysis

The voting results demonstrated strong consensus across all shareholder categories. The Promoter and Promoter Group, holding 78,357,892 shares, voted 100% in favor of all resolutions. Public institutional investors, representing 59,356,787 shares, showed participation rates of 84.44% with approval rates exceeding 98% across all resolutions.

Public non-institutional shareholders, despite lower participation at 6.74%, maintained consistent support with approval rates above 98% for all appointments. The minimal dissent across categories reflects confidence in the proposed leadership structure.

Regulatory Compliance and Documentation

The postal ballot process was conducted under the supervision of Mr. Ashish Bhatt of Ashish Bhatt & Associates, who served as the appointed scrutinizer. The scrutinizer's report, dated March 24, 2026, confirmed the validity of all votes and the proper conduct of the e-voting process. The results were declared in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring transparency and regulatory adherence throughout the process.

J b chemicals and pharmaceuticals Ltd has received a significant penalty order from tax authorities in Tamil Nadu, as disclosed in a regulatory filing under SEBI Listing Regulations. The pharmaceutical company received the order on March 18, 2026 at 7:23 pm from the State Tax Officer, Intelligence, Chennai.

Penalty Details and Nature of Order

The tax authority has imposed a penalty of ₹80.81 crore under Section 74 of the Goods and Service Tax Act, 2017. The order specifically addresses alleged violations related to tax liability differences between the company's tax returns and books of accounts.

Alleged Violations and Period Covered

The order alleges reversal of tax liability for differences identified between tax returns filed and the company's books of accounts. The violations pertain to the financial period from April 2019 to March 2020, indicating the penalty relates to historical tax compliance matters.

Company's Response and Expected Impact

J.B. Chemicals & Pharmaceuticals has outlined its strategy to challenge the penalty order through the appellate process. The company's assessment indicates confidence in achieving a favorable outcome at the appellate level.

The company has specifically stated that based on its assessment, it does not reasonably expect the order to have any material financial impact on its operations. This disclosure was made pursuant to Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring transparency with stakeholders regarding regulatory developments that could potentially affect the company's financial position.